IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Martin Hendrix et al. Serial No.: 10/556,224 Group Art Unit: 1624 Filed: September 27, 2006 Examiner: Susanna Moore 6-CYCLYMETHYL- AND 6-ALKYLMETHYL PYRAZOLO[3,4-D] For: PYRIMIDINES, METHODS FOR THEIR PREPARATION AND METHODS FOR THEIR USE TO TREAT IMPAIRMENTS OF PRECEPTION, CONCENTRATION LEARNING AND/OR MEMORY **INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98** Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Sir: This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows: Timing and Fees \boxtimes Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information disclosure statement is filed: within three months of the filing date of a national application other than a CPA under § 1.53(d); within three months of the actual filing date of the national phase of a PCT application; OR \boxtimes before the mailing of a first substantive office action (including after filing of an RCE). Under 37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods specified in 37 C.F.R. § 1.97(b), but before the mailing date of: a final rejection under 37 C.F.R. 1.113;

a notice of allowance under 37 C.F.R. § 1.311; and

termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR

		is accompanied by:		
			the statement as specified in 37 C.F.R. § 1.97(e) set out below;	
			a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p); or	
			payment by credit card via EFS covering the fee of \$180.00 under 37 C.F.R. § 1.17(p); or	
			R. § 1.97(d), this information disclosure statement is filed after the mailing lowing actions which have not been withdrawn:	
		a final	action under 37 C.F.R. § 1.113;	
		termin	ation of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);	
		OR a r	notice of allowance under 37 C.F.R. § 1.311;	
	AND	AND is filed on or before payment of the issue fee; AND is accompanied by:		
			tement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of 00 under 37 C.F.R. § 1.17(p).	
Staten	nents U	nder 37	C.F.R. 1.97(e)	
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or	
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.	
Cited	Materia	<u>ls</u>		
		ancest	s of materials listed but not attached were cited in benefit (35 U.S.C. § 120) or application Serial No, on Form 892 by the Examiner and/or Form by the applicant; see 37 C.F.R. § 1.98(d).	
		_	s of materials listed but not attached were cited in an international search dated	
			2	

	\boxtimes	Not required by 37 CFR § 1.98.		
		Copies of the materials listed are attached (except for the foregoing).		
Non-E	English I	Language References		
		An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).		
		A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:		
		 X = document of particular relevance when it is taken alone Y = document of particular relevance when it is combined with another such document A = document defining the general state of the art O = non-written disclosure P = intercalated document T = document cited to understand the theory or principle underlying the invention E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date D = cited in the application L = cited for another reason & = publication of member of same patent family Translation of other relevant information on foreign search report 		
<u>Other</u>	Informa	<u>ution</u>		
Payme		ees Due (If Any): ck for \$ covering the fee identified above is attached.		
	Payment by credit card via EFS for \$ covering the fee identified above.			
П	Please charge to Deposit Account No. 13-3402 \$ for the fee identified above.			

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402.

Respectfully submitted,

/John A. Sopp/

John A. Sopp, Reg. No. 33,103 Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza 1 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703) 243-6333 Facsimile: (703) 243-6410

Attorney Docket No.: 01-2116

Date: March 9, 2011

JAS:aew